INS and type 2 diabetes mellitus: Thus, dapagliflozin was a therapeutic alternative for intensification treatment in T2DM patients with uncontrolled glycemia, which has greater effectiveness than other available options (such as DPP-4 inhibitors and insulin) without a significant economic impact and even making cost savings.